ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022
Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 49 citations in OpenAlex.
- New insights into breast cancer therapy: application and mechanisms of novel targeted nano-formulation.International journal of pharmaceutics: X · 2026Review
- Applications of Nanobiotechnology in Medicine.Life (Basel, Switzerland) · 2026Review
- Sorafenib nanomedicine in HCC: nano-bio interactions and combination therapies.Journal of nanobiotechnology · 2026Review
- Emerging nano-immunotherapeutic strategies achieve metastatic colorectal cancer precision therapy.Journal of nanobiotechnology · 2026Review
- Advancements in nanomedicines for cancer therapy: targeting molecular signaling pathways, activating immune cells, and using photothermal immunomodulation.Frontiers in bioengineering and biotechnology · 2026Review
- Natural Product-Based Nanomicelles: Properties, Fabrication Strategies, and Therapeutic Applications in Diseases.International journal of nanomedicine · 2026Review
- Bi-Functional Topospecific Nanoparticles to Promote Immune-Tumor Cell Engagement as A New Immunotherapeutic Strategy.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Recent advances in ultrasound-targeted nanobubbles combined with cancer immunotherapy: Mechanisms, applications, and challenges.Fundamental research · 2026Review
- Nanoparticle Drug Delivery Systems: The Future Direction for the Treatment of Tumors.International journal of nanomedicine · 2026Review
- Rapid-Turnaround Co-Administration of mRNA-Based MHC-I and MHC-II-Restricted Neoantigens Enhances Immune Responses of Antigen-Specific CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- NIR light-driven transformable liquid metal-based nanovaccines restrain postoperative colorectal cancer recurrence.Bioactive materials · 2025Article
- Advances in nanotechnology-enabled adjuvants for peptide-based cancer vaccines.Nano research · 2025Article
- Emerging advances in drug delivery systems (DDSs) for optimizing cancer complications.Materials today. Bio · 2025Review
- Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges.Molecular cancer · 2025Review
- Engineering Nanoparticles to Modulate Extracellular Matrix and Immune Components of the Tumor Microenvironment in Cancer Immunotherapy.Biomaterials research · 2025Review
- Nanoengineered-based delivery systems to modulate CD4Frontiers in pharmacology · 2025Review
- Immunocyte membrane-derived biomimetic nano-drug delivery system: a pioneering platform for tumour immunotherapy.Acta pharmacologica Sinica · 2024Review
- Therapeutic Applications of Nanomedicine: Recent Developments and Future Perspectives.Molecules (Basel, Switzerland) · 2024Review
- Advancements in nanomedicine delivery systems: unraveling immune regulation strategies for tumor immunotherapy.Nanomedicine (London, England) · 2024Review
- Biomaterials Facilitating Dendritic Cell-Mediated Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
With the rapid growth of advanced nanoengineering strategies, there are great implications for therapeutic immunostimulators formulated in nanomaterials to combat cancer. It is crucial to direct immunostimulators to the right tissue and specific immune cells at the right time, thereby orchestrating the desired, potent, and durable immune response against cancer. The flexibility of nanoformulations in size, topology, softness, and multifunctionality allows precise regulation of nano-immunological activities for enhanced therapeutic effect. To grasp the modulation of immune response, research efforts are needed to understand the interactions of immune cells at lymph organs and tumor tissues, where the nanoformulations guide the immunostimulators to function on tissue specific subsets of immune cells. In this review, recent advanced nanoformulations targeting specific subset of immune cells, such as dendritic cells (DCs), T cells, monocytes, macrophages, and natural killer (NK) cells are summarized and discussed, and clinical development of nano-paradigms for targeted cancer immunotherapy is highlighted. Here the focus is on the targeting nanoformulations that can passively or actively target certain immune cells by overcoming the physiobiological barriers, instead of directly injecting into tissues. The opportunities and remaining obstacles for the clinical translation of immune cell targeting nanoformulations in cancer therapy are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.